The $6.9 billion abortion pill industry faces threats amid legal battles and FDA safety reviews. Mifepristone, used with misoprostol, accounts for two-thirds of U.S. abortions. Despite Trump-era power, manufacturing hasn’t slowed. The FDA approved a generic version, but new restrictions could impact access, supply chain, and pharmacy compliance.

The FDA’s approval of Evita’s generic pill expands the mifepristone market. Trump-appointed FDA officials may tighten restrictions on telehealth and mail-order prescriptions. Safety review studies have been criticized as flawed. The Comstock Act could be revived to block drug shipments, affecting abortion access nationwide.

Drugmakers like Danco Laboratories, GenBioPro, and Evita Solutions are exploring new products and uses to mitigate potential crackdowns on mifepristone. Legal battles continue, with companies seeking federal approval authority. State-level differences in abortion policy impact access, with bans on mail-order pills proving difficult to enforce.

States like Texas, Louisiana, and Idaho have expanded penalties for mailing abortion pills. Legal action has had a chilling effect on providers prescribing mifepristone. California and New York have strengthened laws protecting providers treating out-of-state patients, but clinics are struggling due to funding cuts and staff shortages.

Read more at CNBC: Abortion pill mifepristone access steady under Trump, FDA review looms